Memantine Grindeks (Memantine Hydrochloride)

• Memantine is used in the management of neurodegenerative conditions that involve glutamate‑mediated excitotoxicity.
• Alzheimer's disease: improves cognition and functional abilities in mild‑to‑moderate stages.

• Memantine acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel, it reduces excessive calcium influx caused by prolonged glutamate activation, thereby decreasing neuronal excitotoxicity and helping to preserve synaptic function in the brain.

Common Side Effects

• Dizziness: transient light‑headedness reported by some patients.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Constipation: reduced bowel movements, manageable with diet.
• Fatigue: feeling of tiredness, usually improves over time.
• Hypertension: modest increase in blood pressure in a minority.
• Confusion: occasional episodes of mental clouding.

Serious or Rare Side Effects

• Seizures: rare but may occur, especially in patients with a seizure history.
• Cardiac arrhythmia: uncommon irregular heart rhythms.
• Hepatic injury: elevated liver enzymes reported in isolated cases.
• Stevens‑Johnson syndrome: severe skin reaction, extremely rare.
• Psychosis: emergence of hallucinations or delusions in susceptible individuals.
• Suicidal thoughts: rare emergence of suicidal ideation.

• Memantine should be used with caution in specific clinical situations.
• Renal impairment: dose adjustment may be required in patients with reduced kidney function.
• Hepatic impairment: monitor liver function tests during therapy.
• History of seizures: assess risk and consider alternative therapy.
• Concurrent NMDA antagonists: avoid combining with other agents that block NMDA receptors.
• Pregnancy and lactation: insufficient data; use only if potential benefit justifies potential risk.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several medicines that affect the central nervous system.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neuropsychiatric effects.
• Ketamine: combined NMDA blockade can lead to excessive sedation or cognitive impairment.

Moderate Interactions (Monitor Closely)

• Anticholinergics: may diminish cognitive benefits of memantine.
• Diuretics: can potentiate hypotensive effects.
• CNS depressants (e.g., benzodiazepines): increased risk of drowsiness and coordination problems.